LC-MS/MS based assays have seen wide adoption for the quantification of therapeutic peptides and proteins in biological matrices. The typical procedure for a protein therapeutic is enzymatic digestion and quantification of either universal or signature peptides depending on the matrix background. In recent years immunoaffinity sample preparation techniques for sample purification and enrichment before digestion have been widely investigated. There are multiple reasons for the implementation of hyphenated immunocapture-LCMS/MS. One of the key benefits is the significant increase in selectivity and sensitivity that can be achieved by combining the two techniques in addition to wide dynamic range and excellent robustness and reproducibility.
Routinely, immunoaffinity prepared samples are analyzed by signature peptide quantification on triple quadrupoles. In this study, we present an immunoaffinity high resolution accurate mass (HRAMS) assay as a complementary analytical technique for signature peptide quantification. The assay performance is measured using Trastuzumab in rat plasma as a case study.
To download your copy of this technical note complete the form opposite.
Registrants for this application note are covered by the Eclipse Business Media Privacy Policy.
By submitting your information, you agree that SCIEX may collect and further process your personal data in accordance with its Privacy Policy.
Eclipse Business Media Ltd, Regd in England, No. 06513189, Woodview, Bull Lane Industrial Estate, Sudbury, CO10 0FD, United Kingdom, T +44 (0)161 818 7434, info@sepscience.com
Eclipse Business Media Ltd needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy or contact privacy@labxmediagroup.com
Copyright © 2023. All rights reserved